TY - JOUR
T1 - Host S-nitrosylation inhibits clostridial small molecule-activated glucosylating toxins
AU - Savidge, Tor C.
AU - Urvil, Petri
AU - Oezguen, Numan
AU - Ali, Kausar
AU - Choudhury, Aproteem
AU - Acharya, Vinay
AU - Pinchuk, Irina
AU - Torres, Alfredo G.
AU - English, Robert D.
AU - Wiktorowicz, John E.
AU - Loeffelholz, Michael
AU - Kumar, Raj
AU - Shi, Lianfa
AU - Nie, Weijia
AU - Braun, Werner
AU - Herman, Bo
AU - Hausladen, Alfred
AU - Feng, Hanping
AU - Stamler, Jonathan S.
AU - Pothoulakis, Charalabos
N1 - Funding Information:
This work was supported by the Eli & Edith Broad Foundation, the John S. Dunn Gulf Coast Consortium for Chemical Genomics Robert A. Welch Collaborative Grant Program, the Howard Hughes Medical Institute and grants from the US National Institutes of Health National Institute of Allergy and Infectious Diseases (R01AI088748, N01AI30050), National Institute of Diabetes and Digestive and Kidney Diseases (R01DK084509, K01DK076549; R21-DK078032-01), National Heart, Lung, and Blood Institute (R01-HL059130, R01-HL091876, R01-HL095463, P01-HL075443-06A, NO1-HV-00245) and 1UL1RR029876-01. We thank D. Powell, S. Weinman, C.S. Schein and G. Prestwich for their critiques.
PY - 2011/9
Y1 - 2011/9
N2 - The global prevalence of severe Clostridium difficile infection highlights the profound clinical significance of clostridial glucosylating toxins. Virulence is dependent on the autoactivation of a toxin cysteine protease, which is promoted by the allosteric cofactor inositol hexakisphosphate (InsP 6). Host mechanisms that protect against such exotoxins are poorly understood. It is increasingly appreciated that the pleiotropic functions attributed to nitric oxide (NO), including host immunity, are in large part mediated by S-nitrosylation of proteins. Here we show that C. difficile toxins are S-nitrosylated by the infected host and that S-nitrosylation attenuates virulence by inhibiting toxin self-cleavage and cell entry. Notably, InsP 6-and inositol pyrophosphate (InsP 7)-induced conformational changes in the toxin enabled host S-nitrosothiols to transnitrosylate the toxin catalytic cysteine, which forms part of a structurally conserved nitrosylation motif. Moreover, treatment with exogenous InsP 6 enhanced the therapeutic actions of oral S-nitrosothiols in mouse models of C. difficile infection. Allostery in bacterial proteins has thus been successfully exploited in the evolutionary development of nitrosothiol-based innate immunity and may provide an avenue to new therapeutic approaches.
AB - The global prevalence of severe Clostridium difficile infection highlights the profound clinical significance of clostridial glucosylating toxins. Virulence is dependent on the autoactivation of a toxin cysteine protease, which is promoted by the allosteric cofactor inositol hexakisphosphate (InsP 6). Host mechanisms that protect against such exotoxins are poorly understood. It is increasingly appreciated that the pleiotropic functions attributed to nitric oxide (NO), including host immunity, are in large part mediated by S-nitrosylation of proteins. Here we show that C. difficile toxins are S-nitrosylated by the infected host and that S-nitrosylation attenuates virulence by inhibiting toxin self-cleavage and cell entry. Notably, InsP 6-and inositol pyrophosphate (InsP 7)-induced conformational changes in the toxin enabled host S-nitrosothiols to transnitrosylate the toxin catalytic cysteine, which forms part of a structurally conserved nitrosylation motif. Moreover, treatment with exogenous InsP 6 enhanced the therapeutic actions of oral S-nitrosothiols in mouse models of C. difficile infection. Allostery in bacterial proteins has thus been successfully exploited in the evolutionary development of nitrosothiol-based innate immunity and may provide an avenue to new therapeutic approaches.
UR - http://www.scopus.com/inward/record.url?scp=80052483609&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052483609&partnerID=8YFLogxK
U2 - 10.1038/nm.2405
DO - 10.1038/nm.2405
M3 - Article
C2 - 21857653
AN - SCOPUS:80052483609
SN - 1078-8956
VL - 17
SP - 1136
EP - 1142
JO - Nature Medicine
JF - Nature Medicine
IS - 9
ER -